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ANTIBIOTIC SELECTION PRESSURE 
Antibiotic selection pressure is defined with reference 
to the environmental conditions promoting the emer- 
gence and spread of antimicrobial resistance, whatever 
the mechanism of resistance. Antibiotic exposure is 
considered as essential for the emergence of resistance, 
and there is universal agreement that increasing anti- 
microbial resistance is related to the selective pressure 
exerted by the use of antibiotics [l]. Studies on anti- 
biotic selective pressure are generally focused on only 
one aspect of the problem (genes, bacteria, individuals, 
population) (Figure 1). These aspects correspond to a 
specific scientific approach (genetic, cellular, clinical, 
epidemiologic). Now it is time to consider antimicrobial 
resistance as an environmental problem and to develop 
a pharmacoepidemiologic approach, tahng into account 
the individual's antimicrobial exposure and cross-trans- 
mission as well as genetic, cellular, individual and 
population effects. This is required to improve know- 
ledge on population dynamics of resistance, develop 
epidemiologic models which would predict the evolu- 
tion of antimicrobial drug resistance and to find the best 
strategies for the optimal use of antibiotics with regard 
to the control of antimicrobial resistance. The lack of 
such studies has limited our knowledge and under- 
standing ofbacterial resistance dynamics in populations. 
As a result, policies regarding antibiotic treatment of 
outpatients have been hindered. 
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PENICILLIN-RESISTANT srwrococcus PNEUMONIAE 
The risk factors 
In the community, the spread of drug-resistant Strepto- 
coccus pneumoniae is now particularly worrying, especially 
because of the increase of high-level third-generation 
cephalosporin resistance and increasing multiresistance. 
In France, the resistance rates for 1995 and 1996 were 
respectively: for penicillin, 65.4% and 70.3% (18.6% 
and 24.9% of intermediately resistant strains, 46.8% 
and 45.4% of fully resistant strains); for erythromycin, 
57.5% and 68.5%; for tetracycline, 43.2% and 42.6%; 
and for trimethoprim-sulfamethoxazole, 47.5% and 
50.9% [2]. 
Many authors have suggested that the dominant 
factor in the spread of penicillin-resistant Streptococcus 
pneumoniae (PRSp) in the community is the increasing 
use of antibiotics [ 1,3]. Ecological correlations have 
been found between invasive PRSp and antibiotic use 
in the community [4], and time concordance can be 
observed. These analyses do not allow an estimate of 
the risk, and the chain of causality remains unclear. 
Futhermore, while carriage of pneumococci is the 
precondition for interindividual transmission, most 
epidemiologic studies estimating the risk of PRSp with 
p-lactam use have been focused on invasive strains. 
Few pharmacoepidemiologic studies have analyzed 
the risk factors associated with drug-resistant pneumo- 
coccal pharyngeal carriage. Among these risk factors, 
recent p-lactam use is the most consistent [5,6]. Never- 
theless, these studies do not explain how antimicrobial 
drug use is a risk factor for human colonization by 
PRSp and for its diffusion throughout the population. 
The causality 
From an epidemiologic point of view, the criteria for 
the causal nature of an association are the agreement 
with existing information (biological plausibility), the 
consistency of the association, the time sequence, 
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Figure 1 Antibiotic selection pressure. 
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the specificity of the association, and the strength of 
the association (quantitative strength, dose-response 
relationship and study design) [7]. I n  the case of studies 
of PKSp and p-lactam use, most of these criteria are 
satisfied. 
To test the hypothesis that PRSp carriage is related 
to daily dose and duration of p-lactam use, we con- 
ducted a study of pharyngeal carriage of S. pnetrmoniae 
and antimicrobial use in children. This 1995 study was 
published at the beginning of 1998 [8].  It explored 
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Figure 2 Sensitivity of S. pneumoniae and percentile of daily dose of p-lactam: AMX, aminopenicillin; CDX, cefadroxil; 
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Figure 4 Frequency of antibiotic prescription according to different respiratory tract infections (source: IMS-DOREMA) [ 181. 
We calculated the percentile of the daily dose for each 
antibiotic generic and defined two classes with reference 
to the median (greater or lower than the median). 
Considering children with pneumococcal carriage who 
used a p-lactam during the previous month, the median 
daily dose in mg/kg was 46.2 for amoxycillin, 31.8 for 
cefaclor, 43.5 for cefadroxil, 41.6 for cefatrizin, 23.4 for 
cefuroxime axetil, 8.4 for cefpodoxime proxetil and 8.9 
for cefixime. Seventy-seven per cent of the S. pneu- 
moniae isolates from children who had not taken a 
p-lactam had a penicillin G MIC lower than 0.1 mg/L. 
All of the S. pneumoniae isolates from children who 
had taken a daily dose of p-lactam lower than the 
median had a penicillin G MIC higher than 0.1 mg/L. 
In contrast, all S. pneumoniae isolates from children 
who had a daily dose of p-lactam higher than the 
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median had a penicillin G MIC lower than 0.1 mg/L 
(p=0.003) (Figure 2) .  These two groups did not have 
different mean durations of treatment, or different 
mean numbers of daily doses. Grouped according to 
the combined value for daily dose and duration of 
aminopenicillin and cephalosporin of the last P-lactam, 
the percentage of low dose with a long duration was 
46.6%, and that of high dose or short duration 39.1%. 
As compared with no  use, low dose with a long 
duration of treatment was associated with an increased 
risk of PRSp carriage, for both aminopenicillin and 
cephalosporin (Figure 3). 
Even with all epidemiologic criteria, the chain of 
causality remains unclear. The two determinants for 
the spread of PRSp in the community are antibiotic 
selective pressure in individuals and interindividual 
transmission [9]. Several factors could help to explain 
the antibiotic selective pressure: bacterial antagonism in 
regulating the bacterial flora of the human pharynx 
[lo-121, horizontal gene transfer [13], or the selection 
of mutants of S. pneumoniae, due to a low tissue 
concentration of antibiotic [ 141. Another possibility 
could be the following: when a population of children 
is exposed to an oral P-lactam, the increased risk of 
PRSp carriage might be the result of a difference in 
the average duration of carriage between PRSp and 
PSSp. This difference induces an increased transmission 
of PRSp throughout the population, as suggested in 
recent studies, where PRSp carriage persisted longer 
than that of fully susceptible clones [15]. 
The reversibility 
Can optimal use of antibiotics decrease PRSp evolution? 
In order to answer this question, we have first 
to look at antibiotic prescription in the community. 
An audit of anti-infective prescribing in ofice-based 
medical practice in the Loiret, a French administrative 
‘department’, showed that respiratory tract infections 
with a presumed viral etiology accounted for 36% of 
prescriptions. Furthermore, a high percentage of anti- 
biotic prescriptions in children were underdosed as 
compared to clinical recommendations and, whatever 
the clinical hypothesis, the duration of treatment was 
close to 8 days [16]. 
Furthermore, based on national representative 
samples, we showed that, in France, respiratory tract 
infections with a presumed viral etiology were the most 
frequent infections associated with antibiotic use in 
1980-81. The increase in these antibiotic-treated 
infections between 1980-81 and 1991-92 was 86.2% 
for adults and 115.3% for children [17]. 
In order to control drug-resistant S. pneumoniae, 
community-wide education programs for clinicians 
and the general public are important. Such programs 
should focus on the appropriate use of antibiotics. Our 
investigations identified three main areas for improving 
antimicrobial drug prescribing in order to control 
PRSp: (1) to reduce the number of useless prescriptions 
in respiratory tract infections with a presumed viral 
etiology, especially rhinopharyngitis, which is the main 
community infection associated with antibiotic 
prescription; (2) to increase the prescribed daily dose of 
antimicrobials to the recommended levels; and (3) to 
reduce the duration of treatment. 
THE FUTURE: THE AUBEPPIN PROJECT (AMELIORATION 
DE CUTlLlSATlON DES P-IACTAMINES ET PORTAGE DU 
PNEUMOCOQUE DE SENSIBILITE DIMINUEE A LA 
PENICILLINE G) 
A retrospective analysis based on the French IMS- 
Dorema data showed that, in France, antibiotic pre- 
scription in rhinopharyngitis is not a recent practice 
and did not increase very much between 1984 and 1995 
(Figure 4) [18], suggesting that antibiotic prescription 
in this indication in general practice has not changed 
very much. It may be more difficult to change old 
habits than to change new fashions. The obvious need 
is for long-term educational efforts at different levels, 
to make both general practitioners and patients accept 
a reduction in the number of prescriptions. Another, 
parallel, option is to modify some more practical aspects 
of prescription. For this, we need first to assess the 
effect of changing antibiotic use in terms of dosage and 
duration of treatment. In order to distinguish a possible 
natural decrease in resistance from the impact of 
such an intervention, the methodology must be an 
epidemiologic trial. This is the main objective of the 
AUBEPPIN project. We plan to select at random two 
geographic areas in the Loiret. The first will be the 
site of an intervention aiming to increase the dosage 
above that of the French clinical recommendations and 
to reduce the duration of treatment to 5 days, by 
education programs for clinicians and pharmacists. The 
second will be the control group without any inter- 
vention. The intervention will be conducted between 
October 1999 and April 2000. Before and after the 
intervention, nasopharyngeal carriage of S. pneumoniae 
will be surveyed in the two groups, each containing 
1500 healthy 3-6-year-old schoolchildren, selected by 
sampling schools at random in each group. The parents 
of included children will complete, each month, a short 
questionnaire on physician consultations and diagnosis 
as stated by the practitioner, and drug consumption- 
including the type of drug, the duration of treatment 
and the number of daily doses-over 6 months. The 
main criterion will be the PRSp to PSSp ratio, with an 
expected reduction of 30%. Futhermore, in order to 
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compare the duration of carriage, nasopharyngeal 
cultures will be obtained every 2 weeks for 6 months 
from those children who were the pneumococcal 
carriers at the beginning of the study. In order to take 
into account the inter-individual transmission inside 
the school, there will be a genetic analysis of the strains. 
At least two types of important information can be 
expected from this project: 
the reversibility of the development of penicillin G 
resistance among S. pneumoniae isolates when the 
conditions of use of antibiotics are modified. 
the effect of a simple message-‘to use optimal 
dosage and short duration of treatment’-that could 
be added to other actions aimed at developing 
optimal use of antibiotics, such as reducing the 
number of undue prescriptions. 
In any case, these types of intervention would lead 
to decreased costs and, hopefully, have a positive impact 
on bacterial resistance. 
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